Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
The current gold standard for diagnosing BAM or BAD is
2022-05-27

The current gold standard for diagnosing BAM or BAD is the measurement of BA turnover rate with radiolabelled tauroselcholic (75selenium) Quercitrin (also known as the SeHCAT retention test). SeHCAT test involves the use of a synthetic analogue of naturally occurring conjugated taurocholic acid and
In summary the SAR of a series of
2022-05-27

In summary, the SAR of a series of phenylpropanoic acid-free fatty Teriflunomide receptor agonists is described which resulted in the identification of potent FFA4 agonists. The superior pharmacokinetic properties of compound led to its selection as an in vivo tool compound which afforded robust eff
Lubiprostone Compounds that induce exocytosis in cultured ce
2022-05-27

Compounds that induce exocytosis in cultured Lubiprostone include Ca2+-dependent [14] or Ca2+-independent [15] mechanisms. Ca2+-dependent exocytosis releases soluble enzyme content from lysosomes [16] operating by increasing the cytosolic concentration of Ca2+[13] by recruiting extracellular Ca2+[1
br Acknowledgments The breast cancer laboratory is
2022-05-27

Acknowledgments The breast cancer laboratory is supported by the Australian National Health and Medical Research Council (NHMRC) grants no. 1016701, no. 1024852, no. 1086727; NHMRC IRIISS; the Victorian State Government through VCA funding of the Victorian Breast Cancer Research Consortium and Op
Our extensive preliminary data suggest that the loss of p
2022-05-27

Our extensive preliminary data suggest that the loss of p300 (and resulting H3K27ac) is related to inorganic arsenic related diseases. Therefore, it may open a new avenue for alleviating the consequence of H3K27ac, for example, via boosting CBP enzymatic activity for at least partially compensating
br Acknowledgments This study was financially supported by N
2022-05-27

Acknowledgments This study was financially supported by National Science Center Poland grant No DEC-2011/02/A/NZ4/00031 (KKK), Jagiellonian University Medical College (Poland) grants: K/ZDS/007130 (SM) and K/ZDS/007131 (SM), COST Action CA15135 (DŁ, HS, KKK) and DFG INST 208/664-1 FUGG (HS). Than
br General aspects of HDACs br
2022-05-27

General aspects of HDACs General aspects of HDAC inhibitors Based on the previous elements, inhibitors designed for HDAC have in common a well-admitted pharmacophore model (Fig. 7A). This model is composed of a zinc binding group (ZBG), attached to a linker chain mimicking the lysine side chai
br General aspects of HDACs br
2022-05-27

General aspects of HDACs General aspects of HDAC inhibitors Based on the previous elements, inhibitors designed for HDAC have in common a well-admitted pharmacophore model (Fig. 7A). This model is composed of a zinc binding group (ZBG), attached to a linker chain mimicking the lysine side chai
br Discussion As expected RAS prevalence for treatment exper
2022-05-27

Discussion As expected, RAS prevalence for treatment-experienced patients who failed therapy with first-wave, first-generation drugs telaprevir/boceprevir was higher compared to non-experienced patients likely due to drug-selective pressure. For non-responders to previous therapy, resistance subs
br Conclusions and future perspectives br Declarations of in
2022-05-27

Conclusions and future perspectives Declarations of interest Acknowledgements The authors thank Mrs. Kamala Pandey for the help in the preparation of this manuscript. This work was supported by NIH grants R01HL057531 and R01HL062147. Introduction Separation of short exons by long non-co
Recently it was found that hypoxia
2022-05-27

Recently, it was found that hypoxia results in the phosphorylation of β-catenin at Y654 in a Src-dependent manner (Xi et al., 2013). All β-catenin phosphorylated at this residue was found complexed with Hif1α and it was demonstrated that this β-catenin phosphorylation was required for Src to promote
To date very little is known about the
2022-05-27

To date, very little is known about the GEFs that regulate RhoA during amoeboid migration. GEF-H1, a RhoA GEF, is activated response to microtubule destabilization and promotes amoeboid migration (Eitaki, Yamamori, Meike, Yasui, & Inanami, 2012). Interestingly, the majority of H-Lys(Z)-OH australia
q 10 Due to the high structural similarity
2022-05-26

Due to the high structural similarity between GlxI and FosA, it is possible that GlxI directed evolution experiments could produce FosA enzymatic activity in a GlxI enzyme. Although the current investigation was unable to detect FosA activity by mutation of a key metal liganding residue in the activ
Quercetin The results obtained through in vitro in
2022-05-26

The results obtained through in vitro, in vivo and in silico corroborated with those presented by other works and indicate that CpMutY is involved in oxidative damage repair in this organism. In this regard, MutY conservation in evolutionarily distant bacteria suggests that this protein plays an imp
br Transporter based brain targeting
2022-05-26

Transporter-based brain-targeting nano-DDS Drug delivery to the central nervous system (CNS) is still challenging due to the bloodbrain barrier (BBB)53., 54.. The BBB is a natural defense barrier protecting the Efavirenz synthesis from harmful substances. Since only selected, neutral, lipophilic
8512 records 482/568 page Previous Next First page 上5页 481482483484485 下5页 Last page